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Abstract
Background: Perilipins are proteins localized at the surface of the lipid droplet in adipocytes,
steroid-producing cells and ruptured atherosclerotic plaques playing a role in the regulation of
triglyceride deposition and mobilization. We investigated whether perilipin gene polymorphisms
were associated with obesity, type 2 diabetes, and their related variables (anthropometric variables,
plasma leptin, lipids, glucose and insulin concentrations) in a cross-sectional random sample of 1120
French men and women aged 35 to 65 years old, including 227 obese (BMI ≥ 30 kg/m2) and 275
type 2 diabetes subjects.
Results: Among 7 perilipin polymorphisms tested, only 2 (rs4578621 and rs894160) of them were
frequent enough to be fully investigated and we genotyped the sample using the PCR-RFLP method.
No significant associations could be found between any of these polymorphisms and the studied
phenotypes.
Conclusion: The rs4578621 and rs894160 polymorphisms of the perilipin gene are not major
genetic determinants of obesity and type 2 diabetes-related phenotypes in a random sample of
French men and women.
Background
Perilipins are phosphorylated proteins in adipocytes
localized at the surface of the lipid droplet in adipocytes,
steroid-producing cells and ruptured atherosclerotic
plaques [1-4]. These proteins are essential in the regula-
tion of triglyceride deposition and mobilization [5-7].
When protein kinase A is activated, perilipin A becomes
phosphorylated and translocates away from the lipid
droplet, which allows hormone-sensitive lipase to hydro-
lyse the adipocyte triglyceride core [8,9]. Therefore, peril-
ipin A increases cellular triglyceride storage by decreasing
the rate of triglyceride hydrolysis. Mice knockout for the
perilipin gene are lean, have increased basal lipolysis and
are resistant to diet-induced obesity [10,11]. However,
these mice also develop glucose intolerance and insulin
resistance more readily, probably due to the elevated lev-
els of non-esterified fatty acids.
Several studies determined the level of perilipin expres-
sion according to obesity status. Two studies found obese
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subjects displayed lower levels of perilipin than lean indi-
viduals [7,12] whereas another study showed perilipin
mRNA and protein were elevated in obese subjects [13].
Qi et al. previously showed that polymorphisms in the
perilipin locus were associated with obesity-related phe-
notypes in American and Spanish White women [14,15].
Moreover, they showed that a particular haplotype was
associated with increased obesity risk in Malays and Indi-
ans, but not in Chinese [16]. In this study, we examined
the genetic variability of the perilipin gene and possible
associations with obesity, type 2 diabetes and related phe-
notypes in a French random sample of population.
Results
Table 1 describes the genotyping conditions and frequen-
cies of the 7 tested PLIN SNPs (issued from the NCBI
dbSNP database). DNA from 90 individuals issued from
the population study was used to estimate the SNP fre-
quencies. The rs8179072 (A386V), rs8179070 (R274W),
rs3743373 (E293K) SNPs were not detected at all. Only 1
heterozygote for both the rs6496589 (Pro194Ala) and
rs8179071 (Ser348Leu) SNPs could be found (rare allele
frequency = 0.6 %). Therefore we did not pursue the gen-
otyping of these SNPs. The rare allele frequencies of the
rs4578621 (5'UTR -1234 C>G) and rs894160 (intron 6)
SNPs were 7.6 and 30 % respectively. Therefore, we geno-
typed these two SNPs in the whole population study (n =
1120). There were 958 (85.5%) GG, 153 (13.7 %) GA, 9
(0.8%) AA and 556 (49.6%) GG, 470 (42.0%) GA and 94
(8.4%) AA for the rs4578621 and rs894160 SNPs respec-
tively. These frequencies were not different from the
expected frequencies under Hardy-Weinberg equilibrium.
We compared the genotype distribution of the two SNPs
according to BMI categories (normal weight: BMI<25 kg/
m2, overweight : 25≤BMI<30 kg/m2 and obese : BMI≥30
kg/m2) and diabetes status in men and women separately
(table 2). No significant differences in the SNPs frequency
could be detected between BMI or diabetes categories.
Table 3 and 4 show the impact of the PLIN rs4578621 and
rs894160 SNPs respectively on anthropometric and bio-
logical variables in men and women separately. The
means of anthropometric variables (weight, BMI, waist
and hip circumferences, or waist-to-hip ratio), plasma
lipid (plasma cholesterol, HDL-cholesterol, LDL-choles-
terol, triglycerides) or insulin concentrations were not sta-
tistically different between genotype groups neither in
men nor in women. Men carrying the rare AA genotype of
the rs894160 SNP had lower fasting plasma glucose levels
than GG subjects (5.27 ± 0.64 vs. 5.56 ± 0.90 mmol/L or
1.65 ± 0.12 vs. 1.71 ± 0.15 log-transformed values for AA
vs GG men respectively, p = 0.04 when adjusted for cov-
ariates).
Between the two SNPs, the linkage disequilibrium D' was
0.87 (p < 0.0001), the G allele of the rs4578621 SNPS
being associated with the A allele of the rs894160 SNP,
and the r2 was 0.15. Therefore, three haplotypes covered
99 % of the possible haplotypes (haplotype frequencies,
CG: 0.70, CA: 0.22, GA: 0.07). No significant association
could be found between haplotypes and the phenotypes
studied (data not shown).
Discussion
In the present study, we assessed the impact of the genetic
variability of the PLIN gene on obesity, type 2 diabetes
and related phenotypes in a sample of men and women
issued from a French random sample of population (n =
1120). The genotyping of two common SNPs (rs4578621
Table 1: Description of PLIN SNPs, primers, PCR conditions and restriction enzymes.
SNP Primers PCR (bp) MgCl2 (mM) Ann. temp. RE Size (bp) for the wt 
allele
Size (bp) for the 
mut allele
MAF (%)
rs4578621 F : CAAGCTGGGTGCACTGGC
R : GAGAAATAGAGGAATTAACC
185 0.9 58 MnlI 33+152 33+62+90 7.6
rs6496589 F : CTGCCAACACTCG AGCTG
R : ACCTGACTCTTCCTTGTCT
110 1 60 PstI 72+28 no cut 0.6
rs894160 F1 : GCTGAGACTGAGTCACATGC
R1 : GCTGAGACTGAGTCACATGC
403 0.5 60 - - - -
F2 : CTGTTTGTGGGGCTCCCTCG
R2 : CCTCCCAGATCTTTTAAGAG
126 (nested) 0.5 52 XhoI 126 20+106 30.0
rs8179070 F : CAGCTATCTGCTGCCATC
R : CTCACTGAACTTGTTCTCC
219 0.5 58 MspI 75+144 219 ND
rs3743373 F : CAGCTATCTGCTGCCATC
R : CTCACTGAACTTGTTCTCC
219 0.5 58 BseRI 96+49+45+21+5+3 96+94+21+ 5+3 ND
rs8179071 F : GTAGCAGCCCTGCCAGGCC
R : CCGGCACGTAATGCACCAC
248 0.5 69 BstXI 66+182 66+129+53 0.6
rs8179072 F : GTAGCAGCCCTGCCAGGCC
R : CCGGCACGTAATGCACCAC
248 0.5 69 Hpy188III 248 80+168 ND
F : forward, R : reverse, wt allele : wild-type (common) allele, mut allele : mutant (rare) allele, Ann. : annealing, temp. : temperature, RE: restriction 
enzyme, MAF: minor allele frequency.
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and rs894160, frequency = 7.6 and 30 % respectively)
were performed. No significant associations could be
detected between these SNPs and the anthropometric var-
iables, plasma leptin, lipids, glucose and insulin concen-
trations, even when using haplotype analyses.
The only significant association we found in our study was
that men carrying the rare AA genotype of the rs894160
SNP (also called11482 G>A) had significant lower fasting
plasma glucose levels than GG subjects but this difference
was statistically borderline (p = 0.04) and clinically mar-
ginal (around 5% lower) and therefore this association is
not clinically of great consequence and probably obtained
by hazard. Moreover, this polymorphism was not associ-
ated with type 2 diabetes neither in men, nor in women in
our study. Although the 11482 G>A SNP seems to have a
functional impact on the perilipin protein activity as Mot-
tagui-Tabar et al. reported that the A allele was associated
with enhanced basal and noradrenaline-induced lipolysis
in human subcutaneous fat cells [7], it does not seem to
have a major impact in human French populations.
Other studies have previously described associations
between PLIN SNPs and obesity-related phenotypes, espe-
cially the rs894160 (11482 G>A) SNP. Qi L et al. showed
that a PLIN  specific haplotype was associated with an
increased risk of obesity in Malays, Indians and Whites
(odds ratio around 1.7) [14-16]. In Whites, the PLIN
11482 G>A was associated with obesity risk in women but
not in men. We were not able to reproduce this associa-
tion in our French study. Although our study bears on a
large number of subjects (573 men, 547 women), its sta-
tistical power may still be insufficient to detect small asso-
ciations. This hypothesis is supported by an a posteriori
calculation which indicates that according to the observed
allele distribution, the sample size has sufficient statistical
power (1-β≥ 80%) to detect an odds ratio above 2.4 and
2.1 for obesity and 2.1 and 1.8 for type 2 diabetes for the
rs4578621 and rs894160 SNPs respectively. Therefore,
only major associations could be detected. Moreover, we
can not exclude that other PLIN SNPs that we did not
explore, taken individually or in haplotype combinations,
might be associated with obesity phenotypes.
Conclusion
In conclusion, the PLIN rs4578621 and rs894160 poly-
morphisms do not seem to be major genetic determinants
of obesity and type 2 diabetes risk in French men and
women. Other larger studies and/or other PLIN SNPs may
need to be studied to conclude definitely about the impact
of the PLIN gene variability on metabolic diseases.
Methods
Study subjects
Participants were recruited within the framework of the
WHO-MONICA population survey conducted from 1995
to 1997 in the Urban Community of Lille in the North of
France. The sample included subjects aged 35–65 years,
randomly selected from the electoral rolls to obtain 200
participants for each gender and 10-year age group
[17,18]. A total number of 601 men and 594 women was
recruited. To our knowledge, no individuals were related.
Table 2: Genotype distribution of the PLIN rs4578621 and rs894160 SNP according to BMI categories and diabetes status
rs4578621 rs894160
CC CG+GG p GG GA AA p
Men Men
BMI<25 kg/m2 (228) 194 (85.1) 34 (14.9) 109 (47.8) 97 (42.5) 22 (9.7)
25≤BMI<30 kg/m2 (238) 204 (85.7) 34 (14.3) ns 113 (47.5) 103 (43.3) 22 (9.2) ns
BMI≥30 kg/m2 (104) 91 (87.5) 13 (12.5) 58 (55.8) 36 (34.6) 10 (9.6)
Non-diabetic (397) 337 (84.9) 60 (15.1) 186 (46.9) 168 (42.3) 43 (10.8)
Diabetic (151 M/160 W) 127 (84.1) 24 (15.9) ns 82 (51.3) 62 (38.7) 16 (10.0) ns
Women Women
BMI<25 kg/m2 (249) 216 (86.8) 33 (13.2) 129 (51.8) 97 (39.0) 23 (9.2)
25≤BMI<30 kg/m2 (172) 145 (84.3) 27 (15.7) ns 87 (50.6) 79(45.9) 6 (3.5) ns
BMI≥30 kg/m2 (123) 103 (83.7) 20 (16.3) 58 (47.2) 54 (43.9) 11 (8.9)
Non-diabetic (439) 382 (87.0) 57 (13.0) 220 (50.1) 188 (42.8) 31 (7.1)
Diabetic (108 M/115 W) 91 (84.3) 17 (15.7) ns 66 (57.4) 39 (33.9) 10 (8.7) ns
Data are n (%). Among the 1120 individuals genotyped, data on BMI or diabetes status were missing for few subjects. M: men, W: women.Journal of Negative Results in BioMedicine 2006, 5:10 http://www.jnrbm.com/content/5/1/10
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The Ethical Committee of Lille University Hospital
(CHRU de Lille) approved the protocol.
After signing an informed consent, participants were
administered a standard questionnaire and physical
measurements were made by a trained nurse. The level of
physical activity was defined as: walking or riding 15 min
or more per day, and/or lifting or carrying heavy objects at
work daily, and/or doing sport or physical exercise more
than 2 hours a week. Current cigarette smokers were
defined as subjects reporting at least one cigarette per day.
Total alcohol intake was expressed as the sum of ml alco-
hol per week from wine, beer, cider and spirits.
The anthropometric measurements included body
weight, waist and hip circumferences. BMI was calculated
according to the Quetelet equation. Blood pressure was
measured on the right arm, with the subject in a sitting
position and after a minimum 5-min rest, using a stand-
ard mercury sphygmomanometer. The mean value of two
consecutive blood pressure readings was taken into
Table 3: Impact of the PLIN rs4578621 SNP on clinical variables in men and women separately
Men Women
CC
487
CG+GG
81
CC
462
CG+GG
80
Weight, kg 79.9 ± 13.6 79.6 ± 12.9 68.1 ± 14.5 70.8 ± 15.2
BMI, kg/m2 26.7 ± 4.2 26.0 ± 3.6 26.4 ± 5.4 27.3 ± 5.9
Waist, cm 96.2 ± 11.0 95.2 ± 9.8 85.3 ± 13.8 87.9 ± 15.0
Hip circ., cm 101.5 ± 7.4 101.6 ± 6.8 103.5 ± 11.6 105.0 ± 12.7
WHR 0.95 ± 0.07 0.94 ± 0.06 0.82 ± 0.08 0.83 ± 0.08
Leptin, ng/mL† 9.48 ± 7.75 18.16 ± 6.59 24.08 ± 13.90 24.17 ± 14.98
Cholesterol, mmol/L 5.88 ± 1.06 5.92 ± 0.94 5.92 ± 1.11 6.08 ± 1.13
HDL-chol., mmol/L 1.34 ± 0.42 1.31 ± 0.36 1.67 ± 0.49 1.66 ± 0.49
LDL-chol., mmol/L 3.86 ± 1.02 3.89 ± 0.86 3.71 ± 1.04 3.90 ± 1.08
Triglycerides, mmol/L † 1.64 ± 1.38 1.69 ± 1.52 1.19 ± 0.80 1.25 ± 1.37
Glucose, mmol/L † 5.66 ± 1.37 5.52 ± 1.45 5.33 ± 1.28 5.56 ± 1.41
Insulin, µU/mL † 12.37 ± 9.35 11.95 ± 10.01 11.63 ± 6.00 12.06 ± 5.84
† These variables were log-transformed to obtain normal distributions. Circ. : circumference. WHR : waist-to-hip ratio. Chol. : cholesterol. Among 
the 1120 individuals genotyped, data on several variables were missing for few subjects.
Table 4: Impact of the PLIN rs894160 SNP on clinical variables in men and women separately
Men Women
GG
281
GA
235
AA
54
GG
272
GA
231
AA
39
Weight, kg 80.2 ± 14.1 79.2 ± 12.8 81.1 ± 13.2 67.5 ± 14.1 69.9 ± 14.6 67.9 ± 16.8
BMI, kg/m2 26.9 ± 4.3 26.3 ± 4.0 26.3 ± 3.7 26.2 ± 5.3 27.0 ± 5.4 26.7 ± 7.1
Waist, cm 96.5 ± 11.4 95.5 ± 10.2 96.3 ± 10.3 84.7 ± 13.4 87.0 ± 14.1 84.3 ± 16.9
Hip circ., cm 101.7 ± 7.5 101.4 ± 7.3 101.4 ± 7.1 102.9 ± 11.1 104.6 ± 11.8 103.7 ± 15.5
WHR 0.95 ± 0.07 0.94 ± 0.07 0.95 ± 0.07 0.82 ± 0.08 0.83 ± 0.08 0.81 ± 0.07
Leptin, ng/mL† 9.60 ± 7.90 9.18 ± 7.55 8.24 ± 6.19 23.12 ± 13.72 25.26 ± 14.52 23.79 ± 13.28
Cholesterol, mmol/L 5.93 ± 1.10 5.83 ± 1.00 5.86 ± 0.90 5.90 ± 1.18 6.01 ± 1.05 5.93 ± 1.11
HDL-chol., mmol/L 1.33 ± 0.41 1.37 ± 0.41 1.24 ± 0.37 1.65 ± 0.51 1.68 ± 0.47 1.69 ± 0.43
LDL-chol., mmol/L 3.90 ± 1.05 3.79 ± 0.96 3.99 ± 0.85 3.69 ± 1.10 3.80 ± 0.99 3.68 ± 1.05
Triglycerides, mmol/L† 1.71 ± 1.42 1.57 ± 1.31 1.68 ± 1.66 1.21 ± 0.87 1.19 ± 0.97 1.16 ± 0.77
Glucose, mmol/L† 5.56 ± 0.90 5.49 ± 0.85 5.27 ± 0.64* 5.40 ± 1.41 5.42 ± 1.71 5.64 ± 1.55
Insulin, µU/mL† 12.52 ± 9.48 11.93 ± 8.16 12.83 ± 13.62 11.47 ± 5.86 11.83 ± 5.87 12.43 ± 7.32
*crude p < 0.03 or p < 0.04 when adjusted for age, BMI, smoking and alcohol consumptions with a recessive model (adjusted means 5.51 ± 0.05 for 
GG vs 5.52 ± 0.05 for GA vs 5.28 ± 0.11 for AA subjects). † These variables were log-transformed to obtain normal distributions. Circ. : 
circumference. WHR : waist-to-hip ratio. Chol. : cholesterol. Among the 1120 individuals genotyped, data on several variables were missing for few 
subjects.Journal of Negative Results in BioMedicine 2006, 5:10 http://www.jnrbm.com/content/5/1/10
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account. From this sample, 232 subjects were obese (BMI
≥ 30 kg/m2).
Individuals with type 2 diabetes (n = 275) were identified
on the basis of a medical diagnosis and/or fasting glycae-
mia ≥ 7 mmol/L (1.26 g/L) and/or on the existence of a
specific treatment or diet [19] in the Lille sample and in
two other representative French samples (Strasbourg,
Toulouse) participating to the risk factor surveys of the
WHO-MONICA project. Control subjects for type 2 diabe-
tes had fasting glycaemia < 6.1 mmol/L (1.10 g/L) and
had no specific treatment or diet for type 2 diabetes.
Laboratory methods
A blood sample of 20 mL was drawn on disodium EDTA
after the subjects had fasted for at least 10 hours. Lipid
and lipoprotein levels were measured in a central labora-
tory Purpan Hospital Biochemical Laboratory (Toulouse).
The quality of biological measures was assessed within the
framework of the MONICA Project. Glucose was meas-
ured by a standard glucose hexokinase method (DuPont
Dimension, Brussels, Belgium). Plasma insulin was meas-
ured by radio-immunoassay (Medgenix Diagnostics, Brus-
sels, Belgium). Plasma total cholesterol and triglyceride
levels were measured by enzymatic methods (DuPont
Dimension Brussels, Belgium). High density lipoprotein
(HDL) cholesterol was measured after sodium phospho-
tungstate/magnesium chloride precipitation (Boehringer
Mannheim, Mannheim, Germany). Low density lipopro-
tein (LDL) cholesterol was calculated with the Friedewald
equation. Plasma leptin levels were measured by radio-
immunoassay (Human leptin RIA kit, Wak-Chemie, Med-
ical GmbH, Germany).
DNA isolation and genotyping
Genomic DNA was extracted from white blood cells iso-
lated from 20 ml of whole blood using a commercially
available DNA isolation kit (DNA extraction kit, Strata-
gene, La Jolla, CA, USA). Genomic DNA was available for
1155 subjects. The PCR and genotyping conditions for the
SNPs (single nucleotide polymorphisms) are described in
table 1. A total of 1120 subjects were genotyped for the
PLIN rs4578621 and rs894160 SNPs.
Statistical analyses
Chi-square analysis or Fisher exact tests were used to com-
pare genotype and allele distributions between groups.
Comparison of differences among genotype groups were
tested using a general linear model (proc GLM). Adjust-
ment variables were : age, alcohol, smoking, and physical
activity for the anthropometric variables and age, BMI,
alcohol, and smoking for the biological variables. A dom-
inant model was tested for the rs4578621 SNP due to the
low number of homozygotes for the rare allele. A domi-
nant and a recessive model were tested for the rs894160
SNP. Analyses were performed with the SAS statistical
software release 8 (SAS Institute Inc, Cary, NC). Haplo-
type analyses were based on the maximum likelihood
model described in and linked to the SEM algorithm
[20,21] and performed using the software developed by
the INSERM U525, Paris, France (available at http://gene
canvas.ecgene.net/downloads.php). Statistical signifi-
cance was defined at the 5% level. Power calculation was
done with the Epi Info 6.04 software available on http://
www.cdc.gov/epiinfo/. The statistical power (1-β) was set
above 80%.
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